KYTX (Kyverna Therapeutics) Total Liabilities: $61.44 Mil (As of Mar. 2026)


KYTX Kyverna Therapeutics Inc KYTX
12 GF Score
Price $8.88
! 1 Warning Sign
View Full Analysis

What is Kyverna Therapeutics Total Liabilities?

Kyverna Therapeutics KYTX +5.21% 12 Total Liabilities is $61.44 Mil as of Mar. 2026. GuruFocus rates KYTX with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Kyverna Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $61.44 Mil.

Kyverna Therapeutics's quarterly Total Liabilities increased from Sep. 2025 ($35.21 Mil) to Dec. 2025 ($61.55 Mil) but then declined from Dec. 2025 ($61.55 Mil) to Mar. 2026 ($61.44 Mil).

Kyverna Therapeutics's annual Total Liabilities declined from Dec. 2023 ($206.59 Mil) to Dec. 2024 ($38.06 Mil) but then increased from Dec. 2024 ($38.06 Mil) to Dec. 2025 ($61.55 Mil).

Kyverna Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Kyverna Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyverna Therapeutics Total Liabilities Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
131.74 140.92 206.59 38.06 61.55

Kyverna Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.65 42.13 35.21 61.55 61.44
KYTX
12GF Score
Kyverna Therapeutics Inc KYTX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyverna Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Kyverna Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=36.487+(25.063+-3.5527136788005E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=61.55

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=293.826-232.276
=61.55

Kyverna Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=29.674+(31.77+3.5527136788005E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=61.44

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=257.024-195.58
=61.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $61.44 Mil mean?
Kyverna Therapeutics (KYTX) has a Total Liabilities of $61.44 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Kyverna Therapeutics and its competitors.
Is Kyverna Therapeutics' Total Liabilities too high?
Kyverna Therapeutics' current Total Liabilities is $61.44 Mil. Overall, Kyverna Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kyverna Therapeutics' Total Liabilities compare to ZURA and CBIO?
Kyverna Therapeutics' Total Liabilities of $61.44 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Kyverna Therapeutics and its competitors. Kyverna Therapeutics's current Total Liabilities is $61.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyverna Therapeutics stock overvalued right now?
Kyverna Therapeutics (KYTX) has a current Total Liabilities of $61.44 Mil. The current Total Liabilities is $61.44 Mil. Kyverna Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Kyverna Therapeutics (KYTX), the current Total Liabilities is $61.44 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kyverna Therapeutics Business Description

Address 5980 Horton Street, Suite 550, Emeryville, CA, USA, 94608
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
12GF Score

Get the complete analysis for KYTX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.88
Price